We depict a potential origin for high IL-1β in human AML, and a type of patient that may be particularly good responder to anti-IL-1β therapies over patients that present with high IL-1β resulting from primary lesions in the signaling pathway downstream of IL-1R1. This evidence concerns the gene IL1B and acute myeloid leukemia.